Your browser doesn't support javascript.
loading
The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer.
Beijert, Irene J; Hagberg, Oskar; Gårdmark, Truls; Holmberg, Lars; Häggström, Christel; Johnston, Allan; Trail, Matthew; Hamid, Sami; Dreyer, Barend A; Padovani, Luisa; Garau, Roberta; Hasan, Rami; Ahmad, Imran; Hendry, David; Compérat, Eva M; Burger, Maximilian; Rouprêt, Morgan; Gontero, Paolo; Ribal, Maria J; van der Kwast, Theo H; Babjuk, Marko; Sylvester, Richard J; Mariappan, Paramananthan; Liedberg, Fredrik; van Rhijn, Bas W G.
Afiliação
  • Beijert IJ; Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
  • Hagberg O; Institution of Translational Medicine, Lund University, Malmö, Sweden.
  • Gårdmark T; Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
  • Holmberg L; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Häggström C; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Northern Registry Centre, Department of Diagnostics and Intervention, Umeå University, Umeå, Sweden.
  • Johnston A; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Trail M; Department of Urology, Ninewells Hospital, Dundee, UK.
  • Hamid S; Department of Urology, Ninewells Hospital, Dundee, UK.
  • Dreyer BA; Department of Urology, Victoria Hospital, Kirkcaldy, UK.
  • Padovani L; Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK.
  • Garau R; Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK.
  • Hasan R; Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; Department of Urology, University Hospital Ayr, Ayr, UK.
  • Ahmad I; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK; School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Hendry D; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Compérat EM; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
  • Burger M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Rouprêt M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Pitié Salpétrière Hospital, AP-HP, GRC n°5, ONCOTYPE-URO, Sorbonne University, Paris, France.
  • Gontero P; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
  • Ribal MJ; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands.
  • van der Kwast TH; Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
  • Babjuk M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna Gener
  • Sylvester RJ; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.
  • Mariappan P; Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; University of Edinburgh, Edinburgh, UK. Electronic address: Param.Mariappan@nhs.scot.
  • Liedberg F; Institution of Translational Medicine, Lund University, Malmö, Sweden; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Skåne University Hospital, Malmö, Sweden. Electronic address: fredrik.liedberg@med.lu.se.
  • van Rhijn BWG; Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg,
Eur Urol ; 2024 Aug 28.
Article em En | MEDLINE | ID: mdl-39209674
ABSTRACT
Grade is an important determinant of progression in non-muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed the prognostic performance of HG/G3 and HG/G2. Three independent cohorts with 9712 primary (first diagnosis) Ta-T1 bladder tumors were analyzed. Time to progression was analyzed with cumulative incidence functions and Cox regression models. Harrell's C-index was used to assess discrimination. Time to progression was significantly shorter for HG/G3 than for HG/G2 in multivariable analyses (cohort 1 hazard ratio [HR] = 1.92; cohort 2 HR = 2.51, and cohort 3 HR = 1.69). Corresponding progression risks at 5 yr were 18%, 20%, and 18% for HG/G3 versus 7.3%, 7.5%, and 9.3% for HG/G2, respectively. Cox models using hybrid grade performed better than models with WHO2004/2016 (all cohorts; p < 0.001). For the three cohorts, C-indices for WHO2004/2016 were 0.69, 0.62, and 0.75, while, for hybrid grade, C-indices were 0.74, 0.68, and 0.78, respectively. Subdividing the HG category into HG/G2 and HG/G3 stratifies time to progression and supports the recommendation to adopt the hybrid grading system for Ta/T1 bladder cancers.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Eur Urol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Eur Urol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda